Real-World Evaluation of Anticoagulant Treatment Patterns in Patients with Atrial Fibrillation: Data from Multicenter ROTA Study; [Atriyal Fibrilasyon Hastalarında Gerçek Yaşam Antikoagülan Tedavi Tercihlerinin Değerlendirilmesi: Çok Merkezli ROTA Çalışması Verileri]
Özet
Objective: Oral anticoagulant therapy is the cornerstone of atrial fibrillation management to prevent stroke and systemic embolism. However, there is limited real-world information regarding stroke and systemic embolism prevention strategies in patients with atrial fibrillation. The aim of the ROTA study is to obtain the real-world data of anticoagulant treatment patterns in patients with atrial fibrillation. Materials and Methods: The ROTA study is a prospective, multicenter, and observational study that included 2597 patients with atrial fibrillation. The study population was recruited from 41 cardiology outpatient clinics between January 2021 and May 2021. Results: The median age of the study population was 72 years (range: 22-98 years) and 57.4% were female. The median CHA2DS2-VASc and HAS-BLED scores were 4 (range: 0-9) and 1 (range: 0-6), respectively. Vitamin K antagonists and direct oral anticoagulants were used in 15.9% and 79.4% of patients, respectively. The mean time in therapeutic range was 52.9% for patients receiving vitamin K antagonists, and 76% of those patients had an inadequate time in therapeutic range with <70%. The most common prescribed direct oral anticoagulants were rivaroxaban (38.1%), apixaban (25.5%), and edoxaban (11.2%). The rate of overuse of vitamin K antagonists and direct oral anticoagulants was high (76.1%) in patients with low stroke risk, and more than one-fourth of patients on direct oral anticoagulant therapy were receiving a reduced dose of direct oral anticoagulants. Among patients who were on direct oral anticoagulant treatment, patients with apixaban treatment were older, had higher CHA2DS2VASc and HAS-BLED scores, and had lower creatinine clearance than the patients receiving other direct oral anticoagulants. Conclusions: The ROTA study provides important real-world information about anticoagulant treatment patterns in patients with atrial fibrillation. © 2023 Turkish Society of Cardiology. All rights reserved.
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Kocabaş, Umut | |
| dc.contributor.author | Ergin, Işıl | |
| dc.contributor.author | Yavuz, Veysel | |
| dc.contributor.author | Murat, Selda | |
| dc.contributor.author | Özdemir, Ibrahim | |
| dc.contributor.author | Genç, Ömer | |
| dc.contributor.author | Altın, Cihan | |
| dc.contributor.author | Tüner, Haşim | |
| dc.contributor.author | Meriç, Bengisu Keskin | |
| dc.contributor.author | Çoner, Ali | |
| dc.contributor.author | Yüce, Elif İlkay | |
| dc.contributor.author | Boyraz, Bedrettin | |
| dc.contributor.author | Aslan, Onur | |
| dc.contributor.author | Dal, Ahmet | |
| dc.contributor.author | Şen, Taner | |
| dc.contributor.author | İbişoğlu, Ersin | |
| dc.contributor.author | Erdoğan, Aslan | |
| dc.contributor.author | Özgeyik, Mehmet | |
| dc.contributor.author | Demir, Mevlüt | |
| dc.contributor.author | Bilgel, Ziya Gökalp | |
| dc.contributor.author | Şengör, Büşra Güvendi | |
| dc.contributor.author | Urgun, Örsan Deniz | |
| dc.contributor.author | Doğduş, Mustafa | |
| dc.contributor.author | Tekin, Deniz Dilan Naki | |
| dc.contributor.author | Çakal, Sinem | |
| dc.contributor.author | Çayırlı, Sercan | |
| dc.contributor.author | Güler, Arda | |
| dc.contributor.author | Karabulut, Dilay | |
| dc.contributor.author | Dalgıç, Onur | |
| dc.contributor.author | Uzman, Osman | |
| dc.contributor.author | Murat, Bektaş | |
| dc.contributor.author | Şahin, Şeyda | |
| dc.contributor.author | Karabulut, Umut | |
| dc.contributor.author | Kıvrak, Tarık | |
| dc.contributor.author | Coşgun, Muharrem Said | |
| dc.contributor.author | Özyurtlu, Ferhan | |
| dc.contributor.author | Kaplan, Mehmet | |
| dc.contributor.author | Özçalık, Emre | |
| dc.date.accessioned | 2026-10-18T20:27:15.100808877Z | |
| dc.date.available | 2026-10-18T20:27:15.100808877Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | Objective: Oral anticoagulant therapy is the cornerstone of atrial fibrillation management to prevent stroke and systemic embolism. However, there is limited real-world information regarding stroke and systemic embolism prevention strategies in patients with atrial fibrillation. The aim of the ROTA study is to obtain the real-world data of anticoagulant treatment patterns in patients with atrial fibrillation. Materials and Methods: The ROTA study is a prospective, multicenter, and observational study that included 2597 patients with atrial fibrillation. The study population was recruited from 41 cardiology outpatient clinics between January 2021 and May 2021. Results: The median age of the study population was 72 years (range: 22-98 years) and 57.4% were female. The median CHA2DS2-VASc and HAS-BLED scores were 4 (range: 0-9) and 1 (range: 0-6), respectively. Vitamin K antagonists and direct oral anticoagulants were used in 15.9% and 79.4% of patients, respectively. The mean time in therapeutic range was 52.9% for patients receiving vitamin K antagonists, and 76% of those patients had an inadequate time in therapeutic range with <70%. The most common prescribed direct oral anticoagulants were rivaroxaban (38.1%), apixaban (25.5%), and edoxaban (11.2%). The rate of overuse of vitamin K antagonists and direct oral anticoagulants was high (76.1%) in patients with low stroke risk, and more than one-fourth of patients on direct oral anticoagulant therapy were receiving a reduced dose of direct oral anticoagulants. Among patients who were on direct oral anticoagulant treatment, patients with apixaban treatment were older, had higher CHA2DS2VASc and HAS-BLED scores, and had lower creatinine clearance than the patients receiving other direct oral anticoagulants. Conclusions: The ROTA study provides important real-world information about anticoagulant treatment patterns in patients with atrial fibrillation. © 2023 Turkish Society of Cardiology. All rights reserved. | |
| dc.identifier.doi | 10.5543/tkda.2022.98455 | |
| dc.identifier.eissn | 1308-4488 | |
| dc.identifier.endpage | 96 | |
| dc.identifier.issn | 1016-5169 | |
| dc.identifier.issue | 2 | |
| dc.identifier.pmid | 36916815 | |
| dc.identifier.scopus | 2-s2.0-85150311273 | |
| dc.identifier.startpage | 88 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/12337 | |
| dc.identifier.volume | 51 | |
| dc.language.iso | en | |
| dc.publisher | Turkish Society of Cardiology | |
| dc.relation.ispartof | Turk Kardiyoloji Dernegi Arsivi | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | anticoagulation | |
| dc.subject | Atrial fibrillation | |
| dc.subject | direct oral anticoagulants | |
| dc.subject | stroke | |
| dc.subject | systemic embolism | |
| dc.subject | Administration, Oral | |
| dc.subject | Adult | |
| dc.subject | Aged | |
| dc.subject | Aged, 80 and over | |
| dc.subject | Anticoagulants | |
| dc.subject | Dabigatran | |
| dc.subject | Embolism | |
| dc.subject | Female | |
| dc.subject | Humans | |
| dc.subject | Male | |
| dc.subject | Middle Aged | |
| dc.subject | Prospective Studies | |
| dc.subject | Pyridones | |
| dc.subject | Rivaroxaban | |
| dc.subject | Vitamin K | |
| dc.subject | Young Adult | |
| dc.subject | acetylsalicylic acid | |
| dc.subject | amiodarone | |
| dc.subject | anticoagulant agent | |
| dc.subject | antivitamin K | |
| dc.subject | apixaban | |
| dc.subject | beta adrenergic receptor blocking agent | |
| dc.subject | clopidogrel | |
| dc.subject | digoxin | |
| dc.subject | diltiazem | |
| dc.title | Real-World Evaluation of Anticoagulant Treatment Patterns in Patients with Atrial Fibrillation: Data from Multicenter ROTA Study; [Atriyal Fibrilasyon Hastalarında Gerçek Yaşam Antikoagülan Tedavi Tercihlerinin Değerlendirilmesi: Çok Merkezli ROTA Çalışması Verileri] | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 6 | |
| rdl.citation.trdizin | 2 | |
| rdl.department | İZMİR EKONOMİ ÜNİVERSİTESİ | |
| rdl.department | KÜTAHYA SAĞLIK BİLİMLERİ ÜNİVERSİTESİ | |
| rdl.department | T.C. SAĞLIK BAKANLIĞI | |
| rdl.department | UŞAK ÜNİVERSİTESİ | |
| rdl.department | GAZİANTEP ÜNİVERSİTESİ | |
| rdl.department | ESKİŞEHİR OSMANGAZİ ÜNİVERSİTESİ | |
| rdl.department | EGE ÜNİVERSİTESİ | |
| rdl.department | BAŞKENT ÜNİVERSİTESİ | |
| rdl.department | ERZİNCAN BİNALİ YILDIRIM ÜNİVERSİTESİ | |
| rdl.department | AYDIN ADNAN MENDERES ÜNİVERSİTESİ | |
| rdl.department | SAĞLIK BİLİMLERİ ÜNİVERSİTESİ | |
| rdl.department | FIRAT ÜNİVERSİTESİ | |
| rdl.oa.status | gold | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | TRDIZIN | |
| rdl.source.index | PUBMED |
